These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 38516234)

  • 1. Management of autoimmune hepatitis induced by hepatitis delta virus.
    Gigi E; Lagopoulos V; Liakos A
    World J Gastroenterol; 2024 Feb; 30(8):799-805. PubMed ID: 38516234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis D: A Review.
    Negro F; Lok AS
    JAMA; 2023 Dec; 330(24):2376-2387. PubMed ID: 37943548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New therapies for hepatitis delta virus infection.
    Loureiro D; Castelnau C; Tout I; Boyer N; Narguet S; Menasria Benazzouz S; Louis Z; Pons-Kerjean N; Giuly N; Marcellin P; Mansouri A; Asselah T
    Liver Int; 2021 Jun; 41 Suppl 1():30-37. PubMed ID: 34155804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beyond bulevirtide: Alternative therapeutic options for the management of hepatitis delta virus.
    Asselah T
    J Viral Hepat; 2023 Apr; 30 Suppl 1():33-38. PubMed ID: 36529713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis D virus: Improving virological knowledge to develop new treatments.
    Khalfi P; Kennedy PT; Majzoub K; Asselah T
    Antiviral Res; 2023 Jan; 209():105461. PubMed ID: 36396025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidemiology, Natural History, and Treatment of Hepatitis Delta Virus Infection in HIV/Hepatitis B Virus Coinfection.
    Ferrante ND; Lo Re V
    Curr HIV/AIDS Rep; 2020 Aug; 17(4):405-414. PubMed ID: 32607773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial.
    Bazinet M; Pântea V; Cebotarescu V; Cojuhari L; Jimbei P; Albrecht J; Schmid P; Le Gal F; Gordien E; Krawczyk A; Mijočević H; Karimzadeh H; Roggendorf M; Vaillant A
    Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):877-889. PubMed ID: 28964701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis Delta Infection: A Clinical Review.
    Pearlman B
    Semin Liver Dis; 2023 Aug; 43(3):293-304. PubMed ID: 37473778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Future treatments for hepatitis delta virus infection.
    Asselah T; Loureiro D; Tout I; Castelnau C; Boyer N; Marcellin P; Mansouri A
    Liver Int; 2020 Feb; 40 Suppl 1():54-60. PubMed ID: 32077603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent treatment advances and practical management of hepatitis D virus.
    Olsen K; Mahgoub S; Al-Shakhshir S; Algieder A; Atabani S; Bannaga A; Elsharkawy AM
    Clin Med (Lond); 2023 Jul; 23(4):403-408. PubMed ID: 37353306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of hepatitis delta and HIV infection.
    Soriano V; de Mendoza C; Treviño A; Ramos-Rincón JM; Moreno-Torres V; Corral O; Barreiro P
    Liver Int; 2023 Aug; 43 Suppl 1():108-115. PubMed ID: 35748639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening for hepatitis D and PEG-Interferon over Tenofovir enhance general hepatitis control efforts in Brazil.
    Goyal A; Romero-Severson EO
    PLoS One; 2018; 13(9):e0203831. PubMed ID: 30192887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistent Control of Hepatitis B Virus and Hepatitis Delta Virus Infection Following REP 2139-Ca and Pegylated Interferon Therapy in Chronic Hepatitis B Virus/Hepatitis Delta Virus Coinfection.
    Bazinet M; Pântea V; Cebotarescu V; Cojuhari L; Jimbei P; Anderson M; Gersch J; Holzmayer V; Elsner C; Krawczyk A; Kuhns MC; Cloherty G; Dittmer U; Vaillant A
    Hepatol Commun; 2021 Feb; 5(2):189-202. PubMed ID: 33553968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis B Virus Therapeutic Agent ARB-1740 Has Inhibitory Effect on Hepatitis Delta Virus in a New Dually-Infected Humanized Mouse Model.
    Ye X; Tateno C; Thi EP; Kakuni M; Snead NM; Ishida Y; Barnard TR; Sofia MJ; Shimada T; Lee ACH
    ACS Infect Dis; 2019 May; 5(5):738-749. PubMed ID: 30408957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of Delta Hepatitis: Today and in the Future - A review.
    Bahcecioglu IH; Sahin A
    Infect Dis (Lond); 2017 Apr; 49(4):241-250. PubMed ID: 28092214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The return of the hepatitis delta virus].
    Zoutendijk R; de Jonge PJ; de Man RA
    Ned Tijdschr Geneeskd; 2016; 160():D70. PubMed ID: 27405575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of delta hepatitis.
    Gunsar F
    Expert Rev Anti Infect Ther; 2013 May; 11(5):489-98. PubMed ID: 23627855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bulevirtide for HBV and HDV infections.
    Yardeni D; Koh C
    Drugs Today (Barc); 2021 Jul; 57(7):433-448. PubMed ID: 34268531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome.
    Keskin O; Wedemeyer H; Tüzün A; Zachou K; Deda X; Dalekos GN; Heidrich B; Pehlivan S; Zeuzem S; Yalçın K; Gürel S; Tabak F; Idilman R; Bozkaya H; Manns M; Yurdaydin C
    Clin Gastroenterol Hepatol; 2015 Dec; 13(13):2342-49.e1-2. PubMed ID: 26044319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis B virus/hepatitis D virus epidemiology: Changes over time and possible future influence of the SARS-CoV-2 pandemic.
    Sagnelli C; Pisaturo M; Curatolo C; Codella AV; Coppola N; Sagnelli E
    World J Gastroenterol; 2021 Nov; 27(42):7271-7284. PubMed ID: 34876788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.